| Year |
Citation |
Score |
| 2023 |
Järvinen J, Montaser AB, Adla SK, Leppänen J, Lehtonen M, Vellonen KS, Laitinen T, Jalkanen A, Elmquist WF, Timonen J, Huttunen KM, Rautio J. Altering distribution profile of palbociclib by its prodrugs. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 192: 106637. PMID 37967656 DOI: 10.1016/j.ejps.2023.106637 |
0.316 |
|
| 2023 |
Zhang W, Vaubel RA, Oh JH, Mladek AC, Talele S, Zhang W, Waller KL, Burgenske DM, Sarkaria JN, Elmquist WF. Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma. Molecular Cancer Therapeutics. PMID 37828724 DOI: 10.1158/1535-7163.MCT-23-0217 |
0.45 |
|
| 2023 |
Zhang W, Oh JH, Zhang W, Rathi S, Larson JD, Wechsler-Reya RJ, Sirianni RW, Elmquist WF. . The Journal of Pharmacology and Experimental Therapeutics. PMID 37827699 DOI: 10.1124/jpet.123.001826 |
0.35 |
|
| 2023 |
Zhang W, Oh JH, Zhang W, Rathi S, Le J, Talele S, Sarkaria JN, Elmquist WF. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors. Pharmaceutical Research. PMID 37589827 DOI: 10.1007/s11095-023-03574-1 |
0.392 |
|
| 2022 |
Oh JH, Power EA, Zhang W, Daniels DJ, Elmquist WF. Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity. The Journal of Pharmacology and Experimental Therapeutics. 383: 44-55. PMID 36279392 DOI: 10.1124/jpet.122.001268 |
0.346 |
|
| 2022 |
Talele S, Zhang W, Chen J, Gupta SK, Burgenske DM, Sarkaria JN, Elmquist WF. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. The Journal of Pharmacology and Experimental Therapeutics. 383: 91-102. PMID 36137710 DOI: 10.1124/jpet.122.001230 |
0.369 |
|
| 2022 |
Rathi S, Griffith JI, Zhang W, Zhang W, Oh JH, Talele S, Sarkaria JN, Elmquist WF. The influence of the blood-brain barrier in the treatment of brain tumours. Journal of Internal Medicine. PMID 35040235 DOI: 10.1111/joim.13440 |
0.334 |
|
| 2021 |
Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, Gupta SK, Bindra RS, Sarkaria JN, Elmquist WF. Brain distribution of berzosertib: an ATR inhibitor for the treatment of glioblastoma. The Journal of Pharmacology and Experimental Therapeutics. PMID 34556535 DOI: 10.1124/jpet.121.000845 |
0.33 |
|
| 2021 |
Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling. Molecular Cancer Therapeutics. PMID 33785646 DOI: 10.1158/1535-7163.MCT-20-0640 |
0.364 |
|
| 2021 |
Griffith JI, Sarkaria JN, Elmquist WF. Efflux Limits Tumor Drug Delivery Despite Disrupted BBB. Trends in Pharmacological Sciences. PMID 33736874 DOI: 10.1016/j.tips.2021.03.001 |
0.377 |
|
| 2020 |
Gampa G, Kenchappa RS, Mohammad AS, Parrish KE, Kim M, Crish JF, Luu A, West R, Hinojosa AQ, Sarkaria JN, Rosenfeld SS, Elmquist WF. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. Scientific Reports. 10: 6524. PMID 32300151 DOI: 10.1038/s41598-020-63494-7 |
0.36 |
|
| 2019 |
Kim M, Laramy JK, Gampa G, Parrish KE, Brundage RC, Sarkaria JN, Elmquist WF. Brain distributional kinetics of a novel MDM2 inhibitor SAR405838: Implications for use in brain tumor therapy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31619389 DOI: 10.1124/Dmd.119.088716 |
0.427 |
|
| 2019 |
Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF. Brain distribution of a panel of EGFR inhibitors using cassette-dosing in wild-type and Abcb1/Abcg2 deficient mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 30705084 DOI: 10.1124/dmd.118.084210 |
0.337 |
|
| 2019 |
Gampa G, Kim M, Mohammad AS, Parrish KE, Mladek AC, Sarkaria JN, Elmquist WF. Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases. The Journal of Pharmacology and Experimental Therapeutics. PMID 30622172 DOI: 10.1124/jpet.118.253708 |
0.422 |
|
| 2019 |
Gampa G, Kenchappa R, Mohammad A, Parrish K, Kim M, Sarkaria J, Rosenfeld S, Elmquist W. SCIDOT-14. ENHANCING BRAIN RETENTION OF A KIF11 INHIBITOR SIGNIFICANTLY IMPROVES ITS EFFICACY IN A MOUSE MODEL OF GLIOBLASTOMA Neuro-Oncology. 21: vi274-vi274. DOI: 10.1093/neuonc/noz175.1150 |
0.369 |
|
| 2018 |
Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharmaceutical Research. 35: 177. PMID 30003344 DOI: 10.1007/s11095-018-2455-9 |
0.328 |
|
| 2018 |
Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, ... ... Elmquist WF, et al. Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier. Molecular Cancer Therapeutics. PMID 29970480 DOI: 10.1158/1535-7163.Mct-17-0600 |
0.345 |
|
| 2018 |
Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF. Pharmacokinetic assessment of cooperative efflux of the multi-targeted kinase inhibitor ponatinib across the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics. PMID 29440450 DOI: 10.1124/jpet.117.246116 |
0.478 |
|
| 2018 |
Gampa G, Kim M, Cook-Rostie N, Laramy J, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF. Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29437873 DOI: 10.1124/dmd.117.079194 |
0.36 |
|
| 2017 |
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, ... ... Elmquist WF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data. Neuro-Oncology. PMID 29016900 DOI: 10.1093/neuonc/nox175 |
0.324 |
|
| 2017 |
Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, et al. Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of poly (ADP-ribose) polymerase inhibition on temozolomide therapy in glioblastoma. Molecular Cancer Therapeutics. PMID 28947502 DOI: 10.1158/1535-7163.MCT-17-0365 |
0.354 |
|
| 2017 |
Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF. Heterogeneous binding and CNS distribution of the multi-targeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma. The Journal of Pharmacology and Experimental Therapeutics. PMID 28847917 DOI: 10.1124/jpet.117.243477 |
0.325 |
|
| 2017 |
Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities? Pharmacological Research. PMID 28634084 DOI: 10.1016/j.phrs.2017.06.008 |
0.301 |
|
| 2017 |
Gampa G, Crish J, Parrish K, Cook-Rostie N, Kim M, Laramy J, Rosenfeld S, Elmquist W. SCDT-19. DELIVERY OF ISPINESIB IS LIMITED BY EFFLUX TRANSPORT AT THE BLOOD-BRAIN BARRIER (BBB) Neuro-Oncology. 19: vi268-vi269. DOI: 10.1093/neuonc/nox168.1102 |
0.344 |
|
| 2016 |
Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ. ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B driven brainstem glioma model. Molecular Cancer Therapeutics. PMID 26883271 DOI: 10.1158/1535-7163.MCT-15-0093 |
0.308 |
|
| 2016 |
Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-Oncology. 18: 27-36. PMID 26359209 DOI: 10.1093/neuonc/nov164 |
0.32 |
|
| 2015 |
Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF. Factors Influencing the CNS Distribution of a Novel PI3K/mTOR Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. The Journal of Pharmacology and Experimental Therapeutics. PMID 26604245 DOI: 10.1124/jpet.115.229393 |
0.354 |
|
| 2015 |
Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Shroeder MA, Sludden J, Boddy AV, Agar NY, Curtin N, Elmquist WF, Sarkaria JN. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Molecular Cancer Therapeutics. PMID 26438157 DOI: 10.1158/1535-7163.Mct-15-0553 |
0.392 |
|
| 2015 |
Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF. Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model. The Journal of Pharmacology and Experimental Therapeutics. 355: 264-71. PMID 26354993 DOI: 10.1124/jpet.115.228213 |
0.369 |
|
| 2015 |
Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, Elmquist WF. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro-Oncology. PMID 25972455 DOI: 10.1093/Neuonc/Nov081 |
0.446 |
|
| 2015 |
Ma D, Calligaris D, Zhang S, Kim M, Mladek A, Bakken K, Carlson B, Schroeder M, Kitange G, Agar N, Elmquist W, Sarkaria J. DDEL-15MANIPULATION OF THE BLOOD-BRAIN-BARRIER RESTORES THE EFFICACY OF MDM2 INHIBITION IN ORTHOTOPIC GLIOBLASTOMA MODELS Neuro-Oncology. 17: v76.3-v76. DOI: 10.1093/Neuonc/Nov212.15 |
0.305 |
|
| 2014 |
Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1292-300. PMID 24875464 DOI: 10.1124/dmd.114.058339 |
0.407 |
|
| 2014 |
Sarkaria JN, Pokorny JL, Mladek AC, Parrish K, Oberoi R, Sio T, Mittapalli RK, Elmquist WF. INFLUENCE OF DRUG DELIVERY ON THERAPEUTIC BENEFIT IN GBM-CDK4 AND MDM2 INHIBITOR COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS Neuro-Oncology. 16: iii33-iii33. DOI: 10.1093/neuonc/nou208.40 |
0.355 |
|
| 2013 |
Oberoi RK, Mittapalli RK, Elmquist WF. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. The Journal of Pharmacology and Experimental Therapeutics. 347: 755-64. PMID 24113148 DOI: 10.1124/jpet.113.208959 |
0.429 |
|
| 2013 |
Sane R, Agarwal S, Mittapalli RK, Elmquist WF. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. The Journal of Pharmacology and Experimental Therapeutics. 345: 111-24. PMID 23397054 DOI: 10.1124/jpet.112.199786 |
0.413 |
|
| 2013 |
Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. Journal of Pharmaceutical Sciences. 102: 1343-54. PMID 23334925 DOI: 10.1002/jps.23450 |
0.447 |
|
| 2013 |
Li L, Agarwal S, Elmquist WF. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 659-67. PMID 23297298 DOI: 10.1124/dmd.112.049254 |
0.385 |
|
| 2013 |
Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. The Journal of Pharmacology and Experimental Therapeutics. 344: 655-64. PMID 23249624 DOI: 10.1124/jpet.112.201475 |
0.42 |
|
| 2013 |
Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 33-9. PMID 23014761 DOI: 10.1124/dmd.112.048322 |
0.416 |
|
| 2013 |
Gummadi T, Dronca RS, Kim C, Kottschade LA, Mittapalli RK, Elmquist WF, Dudek A. Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma. Journal of Clinical Oncology. 31: 9048-9048. DOI: 10.1200/JCO.2013.31.15_SUPPL.9048 |
0.376 |
|
| 2012 |
Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Molecular Cancer Therapeutics. 11: 2183-92. PMID 22891038 DOI: 10.1158/1535-7163.Mct-12-0552 |
0.399 |
|
| 2012 |
Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1612-9. PMID 22611067 DOI: 10.1124/dmd.112.045930 |
0.315 |
|
| 2012 |
Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). The Journal of Pharmacology and Experimental Therapeutics. 342: 33-40. PMID 22454535 DOI: 10.1124/jpet.112.192195 |
0.435 |
|
| 2012 |
Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1164-9. PMID 22401960 DOI: 10.1124/dmd.112.044719 |
0.416 |
|
| 2012 |
Agarwal S, Elmquist WF. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Molecular Pharmaceutics. 9: 678-84. PMID 22335402 DOI: 10.1021/mp200465c |
0.493 |
|
| 2012 |
Wang T, Agarwal S, Elmquist WF. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics. 341: 386-95. PMID 22323823 DOI: 10.1124/jpet.111.190488 |
0.465 |
|
| 2011 |
Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Current Pharmaceutical Design. 17: 2793-802. PMID 21827403 |
0.43 |
|
| 2011 |
Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine. 13: e17. PMID 21676290 DOI: 10.1017/S1462399411001888 |
0.36 |
|
| 2011 |
Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. The Journal of Pharmacology and Experimental Therapeutics. 336: 223-33. PMID 20952483 DOI: 10.1124/jpet.110.175034 |
0.425 |
|
| 2010 |
Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. The Journal of Pharmacology and Experimental Therapeutics. 334: 147-55. PMID 20421331 DOI: 10.1124/jpet.110.167601 |
0.447 |
|
| 2010 |
Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF. Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Molecular Pharmaceutics. 7: 138-45. PMID 19886673 DOI: 10.1021/Mp900177R |
0.374 |
|
| 2009 |
Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. The Journal of Pharmacology and Experimental Therapeutics. 330: 956-63. PMID 19491323 DOI: 10.1124/Jpet.109.154781 |
0.544 |
|
| 2009 |
Shaik N, Giri N, Elmquist WF. Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. Journal of Pharmaceutical Sciences. 98: 4170-90. PMID 19283769 DOI: 10.1002/Jps.21723 |
0.563 |
|
| 2009 |
Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist WF. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 560-70. PMID 19056916 DOI: 10.1124/Dmd.108.022046 |
0.402 |
|
| 2008 |
Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, Elmquist WF. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1476-84. PMID 18443033 DOI: 10.1124/dmd.108.020974 |
0.372 |
|
| 2008 |
Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. Journal of Pharmaceutical Sciences. 97: 5421-33. PMID 18393290 DOI: 10.1002/Jps.21372 |
0.613 |
|
| 2007 |
Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 2076-85. PMID 17709369 DOI: 10.1124/Dmd.107.017723 |
0.594 |
|
| 2007 |
Pan G, Giri N, Elmquist WF. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1165-73. PMID 17437964 DOI: 10.1124/dmd.106.014274 |
0.345 |
|
| 2007 |
Spitzenberger TJ, Heilman D, Diekmann C, Batrakova EV, Kabanov AV, Gendelman HE, Elmquist WF, Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 27: 1033-42. PMID 17063148 DOI: 10.1038/Sj.Jcbfm.9600414 |
0.632 |
|
| 2006 |
Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Research and Treatment. 96: 217-25. PMID 16502018 DOI: 10.1007/S10549-005-9004-Z |
0.33 |
|
| 2005 |
Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharmaceutical Research. 22: 1259-68. PMID 16078135 DOI: 10.1007/s11095-005-5271-y |
0.653 |
|
| 2005 |
Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. The Journal of Pharmacology and Experimental Therapeutics. 315: 222-9. PMID 15987831 DOI: 10.1124/Jpet.105.090043 |
0.612 |
|
| 2005 |
Hitzman CJ, Wiedmann TS, Dai H, Elmquist WF. Measurement of drug release from microcarriers by microdialysis. Journal of Pharmaceutical Sciences. 94: 1456-66. PMID 15920767 DOI: 10.1002/Jps.20349 |
0.533 |
|
| 2004 |
Batrakova EV, Li S, Li Y, Alakhov VY, Elmquist WF, Kabanov AV. Distribution kinetics of a micelle-forming block copolymer Pluronic P85. Journal of Controlled Release : Official Journal of the Controlled Release Society. 100: 389-97. PMID 15567504 DOI: 10.1016/J.Jconrel.2004.09.002 |
0.342 |
|
| 2004 |
Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, de Groot JF, Hickner RC, Cavus I, Grossman SA, Colvin OM. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro-Oncology. 6: 65-74. PMID 14769143 DOI: 10.1215/S1152851703000103 |
0.398 |
|
| 2004 |
Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, Groot JFd, Hickner RC, Cavus I, Grossman SA, Colvin OM. Erratum: "Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium" (Neuro-Oncology (2004) vol. 6 (1)) Neuro-Oncology. 6. DOI: 10.1215/15228517-6-2-172 |
0.305 |
|
| 2003 |
Dash AK, Elmquist WF. Separation methods that are capable of revealing blood-brain barrier permeability. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 797: 241-54. PMID 14630153 DOI: 10.1016/S1570-0232(03)00605-6 |
0.369 |
|
| 2003 |
Batrakova EV, Li S, Alakhov VY, Elmquist WF, Miller DW, Kabanov AV. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharmaceutical Research. 20: 1581-90. PMID 14620511 DOI: 10.1023/A:1026179132599 |
0.354 |
|
| 2003 |
Dai H, Elmquist WF. Drug transport studies using quantitative microdialysis. Methods in Molecular Medicine. 89: 249-64. PMID 12958425 DOI: 10.1385/1-59259-419-0:249 |
0.635 |
|
| 2003 |
Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. The Journal of Pharmacology and Experimental Therapeutics. 304: 1085-92. PMID 12604685 DOI: 10.1124/Jpet.102.045260 |
0.686 |
|
| 2003 |
Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Advanced Drug Delivery Reviews. 55: 83-105. PMID 12535575 DOI: 10.1016/S0169-409X(02)00172-2 |
0.722 |
|
| 2001 |
Sun H, Miller DW, Elmquist WF. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharmaceutical Research. 18: 1542-9. PMID 11758761 DOI: 10.1023/A:1013074229576 |
0.607 |
|
| 2001 |
Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. British Journal of Cancer. 85: 1987-97. PMID 11747344 DOI: 10.1054/Bjoc.2001.2165 |
0.3 |
|
| 2001 |
Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF. Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochemical and Biophysical Research Communications. 284: 863-9. PMID 11409873 DOI: 10.1006/Bbrc.2001.5062 |
0.605 |
|
| 2001 |
Sun H, Bungay PM, Elmquist WF. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. The Journal of Pharmacology and Experimental Therapeutics. 297: 991-1000. PMID 11356921 |
0.592 |
|
| 2001 |
Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. The Journal of Pharmacology and Experimental Therapeutics. 296: 551-7. PMID 11160643 |
0.515 |
|
| 2001 |
Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF. Transport of Fluorescein in MDCKII-MRP1-Transfected Cells and mrp1-Knockout Mice Biochemical and Biophysical Research Communications. 286: 227. DOI: 10.1006/Bbrc.2001.5370 |
0.527 |
|
| 2000 |
Sawchuk RJ, Elmquist WF. Microdialysis in the study of drug transporters in the CNS Advanced Drug Delivery Reviews. 45: 295-307. PMID 11108981 DOI: 10.1016/S0169-409X(00)00104-6 |
0.518 |
|
| 2000 |
Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Research. 876: 148-53. PMID 10973603 DOI: 10.1016/S0006-8993(00)02628-7 |
0.331 |
|
| 2000 |
Elmquist WF, Sawchuk RJ. Use of microdialysis in drug delivery studies Advanced Drug Delivery Reviews. 45: 123-124. DOI: 10.1016/S0169-409X(00)00105-8 |
0.361 |
|
| 1998 |
Fakata KL, Elmquist WF, Swanson SA, Vorce RL, Prince C, Stemmer PM. Cyclosporin a has low potency as a calcineurin inhibitor in cells expressing high levels of p-glycoprotein Life Sciences. 62: 2441-2448. PMID 9651111 DOI: 10.1016/S0024-3205(98)00227-6 |
0.506 |
|
| 1998 |
Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochemical and Biophysical Research Communications. 243: 816-20. PMID 9500978 DOI: 10.1006/Bbrc.1997.8132 |
0.536 |
|
| 1997 |
Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Advances in Enzyme Regulation. 37: 335-47. PMID 9381979 DOI: 10.1016/S0065-2571(96)00021-0 |
0.405 |
|
| 1996 |
Fontaine M, Elmquist WF, Miller DW. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sciences. 59: 1521-31. PMID 8890933 DOI: 10.1016/0024-3205(96)00483-3 |
0.536 |
|
| 1995 |
Wang Q, Yang H, Miller DW, Elmquist WF. Effect of the P-Glycoprotein Inhibitor, Cyclosporine A, on the Distribution of Rhodamine-123 to the Brain: An in Vivo Microdialysis Study in Freely Moving Rats Biochemical and Biophysical Research Communications. 211: 719-726. PMID 7598699 DOI: 10.1006/bbrc.1995.1872 |
0.471 |
|
| Show low-probability matches. |